Dinutuximab
Based on 1 Customer Validation
Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: ≥99.0%
- CAS No.: 1363687-32-4
- 분자량:145.012 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
ganglioside GD2
Dinutuximab (0-5000 ng/mL; 0-12 days) can inhibit the adhesion, migration, and mammosphere formation, induce apoptosis of breast cancer cells MDA-MB-231, and inhibit the phosphorylation of mTOR, ERK, and 4E-BP1[1].
Dinutuximab (100 ng/mL; 6-72 h), when used in combination with in vitro-activated natural killer cells (aNK) in human neuroblastoma cell lines SH-SY5Y-Fluc, CHLA-136-Fluc, and CHLA-255-Fluc, significantly reduces the viability and invasive ability of tumor cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 cells
-
Concentration:0, 500, 1000 and 5000 ng/mL
-
Incubation Time:24 h
-
Result:Inhibited the levels of pmTOR, pERK and p4E-BP1.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG mice aged 6-8 weeks old treated CHLA-136-Fluc, CHLA-255-Fluc or COG-N-415x cells[2]
-
Dosage:15 μg
-
Administration:Tail vein injection; twice a week; 4 weeks
-
Result:Significantly decreased the incidence and quantity of tumor cells in the liver and bone marrow and increased the survival rate of mice when combined with aNK cells.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized Ganglioside GD2 (HY-165740) can bind Dinutuximab. The EC50 for this effect is 931 ng/mL.
Chemical Information
-
CAS No. 1363687-32-4
-
Appearance Liquid
-
분자량 145.012 kDa
-
Color Colorless to light yellow
-
SMILES
[Dinutuximab]
-
Synonyms
APN-311; Ch14.18; MAb-14.18
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Ly S, et al. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. J Immunother Cancer. 2021 Mar;9(3):e001197. [Content Brief]
[2]. Barry WE, et al. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma. Clin Cancer Res. 2019 Jan 1;25(1):325-333. [Content Brief]
[3]. Ploessl C, et al. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma. Ann Pharmacother. 2016 May;50(5):416-22. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Dinutuximab Related Classifications
HY-P9933 Related Classifications
Powered by Bioz